| アブストラクト | BACKGROUND/AIM: Osimertinib is a well-tolerated first- or second-line treatment option for elderly patients with epidermal growth factor receptor mutation-positive advanced non-small cell lung cancer. However, the safety of osimertinib in elderly patients requires further investigation. Herein, we identified safety signals for various osimertinib-related adverse events (AEs) in elderly patients by disproportionality analysis using the Japanese Adverse Drug Event Report (JADER) database. PATIENTS AND METHODS: Data from the JADER database from April 2004 to March 2023 were obtained from the Pharmaceuticals and Medical Devices Agency website. Safety signal detection for osimertinib-related AEs in elderly patients (>/=70 years old) was determined using the relative elderly reporting odds ratio (ROR). For osimertinib-related AEs, we extracted 92 preferred terms (PTs) and nine standardized MedDRA queries (SMQs). RESULTS: Safety signals in elderly patients were detected for "Cardiomyopathy (PT)" and "Cardiomyopathy (SMQ)". The symptoms most frequently associated with "Cardiomyopathy (SMQ)" included "Ejection fraction decreased (PT)", "Cardiomyopathy (PT)", and "Stress cardiomyopathy (PT)". Notably, 53.7% of these outcomes were "Recovery" or "Remission". The median time to the onset of "Cardiomyopathy (SMQ)" in elderly patients was 85 days (range=2-537 days). CONCLUSION: We demonstrated that patients >/=70 years potentially have increased osimertinib-related cardiomyopathy compared with patients <70 years. In the future, it is necessary to conduct research focusing on cardiomyopathy in elderly patients. |
|---|
| ジャーナル名 | Cancer diagnosis & prognosis |
|---|
| Pubmed追加日 | 2024/9/6 |
|---|
| 投稿者 | Omoto, Takashi; Asaka, Junichi; Kudo, Kenzo |
|---|
| 組織名 | Department of Pharmacy, Iwate Medical University Hospital, Shiwa, Japan.;Division of Clinical Pharmaceutics and Pharmacy Practice, Department of Clinical;Pharmacy, School of Pharmacy, Iwate Medical University, Shiwa, Japan. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/39238633/ |
|---|
